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Hepatic nuclear factor 4α (HNF4α) modulates the transcriptional activation of numerous metabolic genes in liver. In this study,
gene-array analysis revealed that HNF4α overexpression increased peroxisome proliferator-activated receptorγ (PPARγ) greatly
in cultured rat primary hepatocytes. PPAR-response-element-driven reporter gene expression could be elevated by HNF4α.
Bioinformatics analysis revealed a high-aﬃnity HNF4α binding site in the human PPARγ2p r o m o t e ra n din vitro experiments
showed that this promoter could be transactivated by HNF4α. The presence of HNF4α on the promoter was then conﬁrmed by
ChIP assay. In vivo, hepatic overexpression of HNF4α decreased cholesterol levels both in plasma and liver and several hepatic
genes related to cholesterol metabolism, including scavenger receptor BI (SR-BI), were upregulated. The upregulation of SR-BI
by HNF4α could be inhibited by a PPARγ antagonist in vitro. In conclusion, HNF4α regulates cholesterol metabolism in rat by
modulating the expression of SR-BI in the liver, in which the upregulation of PPARγ was involved.
1.Introduction
Nuclear receptors are ligand-activated transcription factors
that regulate such diverse physiological processes as repro-
duction, development, and metabolism. Hepatic nuclear fac-
tor 4α (HNF4α) is a member of the nuclear receptor super-
family and plays an essential role in development and fun-
ction in diﬀerent organs, including liver, kidney, intestine,
and pancreatic β cells. HNF4α contributes to gene regulation
of the liver and pancreatic islet by binding directly to many
actively transcribed genes [1]. The role of HNF4α as a meta-
bolic transcriptional regulator in both the liver and pancreas
has been uncovered by transcriptome analysis. Like other
transcriptionfactors,HNF4αmodulatestranscriptionalacti-
vation of genes involved in transportation and metabolism
of glucose, amino acids, lipids, and vitamins and in bile acid
biosynthesis.HNF4αwasonceconsideredanorphannuclear
receptor because its endogenous ligand was not clear. Struc-
tural biology evidence suggests that HNF4α can bind to the
C14 to C18 long-chain fatty acids [2, 3]. Recently, Sladek
group reported that linoleic acid could bind with HNF4α,
butligandoccupancyappearednothavingasigniﬁcanteﬀect
on its transcriptional activity [4]. Thus, HNF4α may be re-
sponsible for a change in metabolic status (e.g., changes in
fatty acid levels) beyond direct transcriptional modulation.
Clinical evidence revealed that loss-of-function muta-
tions in HNF4α cause maturity onset diabetes of the young 1
(MODY1) [5], a type of early-onset diabetes with pancreatic
β cell dysfunction. Patients with MODY1 have decreased
b l o o dt r i g l y c e r i d e sa n dc h o l e s t e r o ll e v e l s[ 6]. Gene variants
of HNF4α are also associated with type 2 diabetes [7, 8].
The mechanism underlying hypolipidemia remains poorly
understood.HNF4α-nullmicedieduringembryogenesis[9],
and mice lacking hepatic HNF4α expression showed in-
creased lipid levels in the liver and greatly disturbed lipid
metabolism. Liver-speciﬁc HNF4α-knockout mice showed
profoundly decreased plasma levels of cholesterol, high-den-
sity lipoprotein-cholesterol (HDL-C), and triglycerides and2 PPAR Research
elevated plasma level of bile acid [10]. Despite the investiga-
tion of numerous genes, the pattern of gene regulation of lip-
id homeostasis by overexpression of HNF4α is still unclear.
Previously, we reported that hyperinsulinemia downreg-
ulated HNF4α and its target genes through the upregulation
of sterol responsive element binding proteins (SREBPs),
other important transcriptional factors regulating cholester-
ol and fatty acid metabolism [11]. To further investigate the
transcription proﬁle of HNF4α in hepatocytes and its cross-
talk with other transcription factors, we used a gain-of func-
tion model with adenovirus encoding HNF4α (Ad-HNF4α)
and microarray analysis in hepatocytes and rat plasma and
liver. Hepatic overexpression of HNF4α led to lower choles-
terol levels both in plasma and liver, and another important
metabolic nuclear receptor, peroxisome proliferator-activat-
ed receptor γ (PPARγ), and a scavenger receptor SR-BI were
involved in the process. Our ﬁndings suggest that hepatic
HNF4α has a more potent role in cholesterol than glucose
and triglycerides metabolism.
2.MaterialandMethods
2.1. Cell Culture and Reagents. The human hepatoma cell
line HepG2 was maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 10% (vol/vol) fetal bovine se-
rum (FBS, Hyclone, Logan, Utah, USA). HEK293 cells were
cultured in DMEM with 5% FBS. Primary isolated and cul-
turedhepatocyteswereobtainedfrom8-week-oldmaleSpra-
gue-Dawley rats by the two-step collagenase perfusion tech-
nique[12].Cells(3 ×106)wereplatedon60-mm rattailcol-
lagen- (Millipore-) coated dishes containing medium 1640
supplemented with 20mM HEPES, 1mM sodium pyruvate,
and 10% FBS for 3 days before treatment. The cells were
infected with the adenovirus described below for 24hr,
then cultured in medium containing the PPARγ antagonist
BADGE (10mM, Sigma, St. Louis, Mo, USA) or the same
volume of relevant vehicle DMSO for an additional 24hr. All
cells were maintained at 37◦Ci n5 %C O 2, 95% air.
2.2. Adenovirus Construction and Infection. Ad-HNF4α was
generatedbyuseoftheAdeno-X Expression System2(Qbio-
gene,Carlsbad,Calif,USA).Theadenovirusvectorwasbased
on replication-deﬁcient E1 and E3 adenovirus under the
transcriptional control of the cytomegalovirus promoter.
ThecDNAencodingafull-lengthratHNF4αwasobtainedby
digestion from the pcDNR-CMV-rHNF4α construct, then
inserted into the pLP-Adeno-CMV construct under the con-
trol of the Cre/loxP system. DNA linearized by PacI digestion
was packaged into the virus in HEK293 cells. The recombi-
nant adenovirus (Ad-CMV-rHNF4α) was grown in HEK293
cells, puriﬁed, and titrated according to the manufacturer’s
instructions. HepG2 and rat primary hepatocytes were incu-
batedwithrecombinantadenovirusatamultiplicityofinfec-
tion (MOI) of 20 for 24hr before experiments.
2.3. RNA Extracts and Quantitative Real-Time PCR Analysis.
Total RNA was extracted by the Trizol Reagent method
(Applygen, Beijing, China). The isolated RNA was convert-
ed into cDNA. Quantitative RT-PCR with the Brilliant SYBR
Green QPCR system involved use of β-actin as an internal
control with the MX3000P QPCR detection system (Strata-
gene, La Jolla, Calif, USA). The primer sequences are in the
supplementary tables. In a separate experiment, the extract-
ed total RNA underwent PCR array of liver-related genes
(SuperArray, SABiosciences, Frederick, Md, USA) by Kang-
cheng Inc. (Beijing, China).
2.4. Western Blot Analysis. Cell lysates and rat liver extracts
were resolved by 10% SDS-PAGE and transferred to a nitro-
cellulosemembrane.ProteinexpressionofsEH,GAPDHand
β-actin was detected by use of polyclonal antibodies anti-
HNF4α (Santa Cruz Biotechnology, Santa Cruz, Calif, USA),
anti-SR-BI (NOVUS Biologicals, Littleton, Colo, USA) and
anti-β-actin (Bioss, Beijing, China) followed by horseradish
peroxidase-conjugated secondary antibody. The protein
bands were visualized by the ECL detection system (Amer-
sham, Stockholm, Sweden), and the densities of the bands
were quantiﬁed by computer-assisted image analysis (NIH
Image J).
2.5. Promoter Reporter Assay. A1 . 6 - k bf r a g m e n to f
PPARγ2 promoter was cloned by PCR from the genome of
the HEK293 cell line with the oligonucleotide primers
5 -TCCAGAAGTGAGACCCTTTG- AG-3  and 5 -
CATGGAATAGGGGTTTGCTGTAAT-3 . The ampliﬁed
fragment was sequenced and then inserted into the EZ-T
construct (Genestar, Beijing, China), then cloned into the
reporter vector pGL3 (Promega, Madison, Wis, USA) on the
SmaIa n dKpnI sites and named PPARγ2-(−1505)-Luc.
PPARγ2-(−893)-Luc and PPARγ2-(−502)-Luc vectors were
constructed by the same strategy. Transfection experiments
were carried out in 24-well plates with use of JetPEITM (Pol-
yPlus-transfection, Illkirch, France). Luciferase and β-galac-
tosidase assays followed the manufacturer’s instructions
(Promega, Madison, Wis, USA).
2.6. Chromatin Immunoprecipitation (ChIP) Assay. ChIP
assays were performed as described [13]. In brief, HepG2
cells were cross-linked and sonicated, then underwent im-
munoprecipitation (IP) with polyclonal anti-HNF4α.N o r -
m a lI g Gw a su s e da sa nI Pc o n t r o l ,a n dt h es u p e r n a t a n tw a s
an input control. After digestion with proteinase K, the rest-
ing DNA was extracted, and the PPARγ2 promoter contain-
ing the HNF4α consensus element was ampliﬁed by PCR
with the primers 5 -TGACAAGACCTGCTCC-3  and 5 -
TACGCTGTTAGGTTGG-3 . The resulting DNA was re-
solvedon2%agarosegelandstainedwithethidiumbromide.
2.7. Animal Experiment. The investigation conformed to the
Guide for the Care and Use of Laboratory Animals published
bytheUSNationalInstitutesofHealth(NIHPublicationNo.
85–23, revised 1996). The animal experimental protocol was
approved by the Peking University Institutional Animal Care
and Use Committee. Sprague-Dawley rats were fed standard
laboratory chow and tap water ad libitum and bred under
a 12-h light/12-h dark cycle. The 8-week-old (∼200g) malePPAR Research 3
Table 1:GenesdiﬀerentiallyregulatedinratprimaryhepatocytesbyadenovirusHNF4α(Ad-HNF4α)relativetoAd-GFPinfectionaccording
to the superarray analysis.
Accession No. Name Description Fold Diﬀerence
NM 022180 HNF4α Hepatocyte nuclear factor 4, alpha 333.14
NM 022215 GPD1 Glycerol-3-phosphate dehydrogenase 1 (soluble) 97.01
NM 013124 PPARγ Peroxisome proliferator activated receptor, gamma 19.29
NM 022852 PDX1 Pancreatic and duodenal homeobox gene 1 7.73
NM 013098 G6PC Glucose-6-phosphatase, catalytic 5.54
NM 133380 IL4R Interleukin 4 receptor 3.10
NM 012524 CEBPα CCAAT/enhancer binding protein (C/EBP), alpha 3.05
NM 013091 TNFRSF1α Tumor necrosis factor receptor superfamily, member 1a 2.23
NM 012565 GCK Glucokinase 2.22
NM 012580 HMOX1 Heme oxygenase (decycling) 1 2.19
NM 138880 IFNγ Interferon gamma −2.01
NM 022944 INPPL1 Inositol polyphosphate phosphatase-like 1 −2.07
NM 022611 IL12β Interleukin 12b −2.17
NM 012544 ACE Angiotensin 1 converting enzyme −2.36
NM 031116 CCL5 Chemokine (C-C motif) ligand 5 −2.57
NM 012589 IL6 Interleukin 6 −4.47
rats were injected with Ad-rHNF4α at 1 × 109 plaque-form-
ing units in 0.5-mL saline through the tail vein. The same
amountofAd-GFPwasinjectedinthecontrolgroup(n = 6).
Levels of plasma glucose were measured by use of a portable
glucometer (ACCU-CHEK II; Roche Diagnostics, Basel,
Swiss). Seven days after the injection, the rats fasted for
6hr and then were anesthetized and killed. Blood samples
were collected from the saphenous vein, and plasma levels of
lipoproteins and insulin were measured. Liver tissues were
dissected after a PBS rinse and stored at −80◦C.
2.8. Measurement of Plasma and Tissue Lipids. Rat plasma
samples were collected, and lipoproteins were separated by
fastperformanceliquidchromatography(FPLC)(Pharmacia
Biotech, Sweden). The levels of cholesterol and triglycerides
in plasma or the FPLC fractions were detected by use of an
automated clinical chemistry analyzer kit (Biosino Biotech
Inc., Beijing, China). For quantiﬁcation of liver cholesterol
and triglycerides, approximately 100mg liver was homog-
enized and the extraction was dissolved with chloroform:
methanol (2:1). The lipid fractions were dried under nitro-
gen gas and re-solubilized by phosphate buﬀered saline con-
taining 1% Triton X-100 before measurement of cholesterol
and triglyceride levels.
2.9. Statistical Analysis. Data were analyzed by the unpaired
Student t test, one-way ANOVA, or Mann-Whitney test
(GraphPad Prism4 software). All values are expressed as
mean ±SEM.Diﬀerenceswereconsideredstatisticallysignif-
icant at P<0.05.
3. Results
3.1. Hepatic HNF4α Induces PPARγ Upregulation and Acti-
vation. Previously, we reported that hepatic HNF4α was
downregulated in db/db diabetic mice [14]. To further in-
vestigate the role of HNF4α in liver metabolism, we over-
expressed HNF4α in rat primary hepatocytes by Ad-rHNF4α
infection and analyzed the expression of liver-related genes
by PCR array. As shown in Table 1, known HNF4α target
genes, such as glucose-6-phosphatase, catalytic subunit
(G6pc) and liver type of pyruvate kinase (L-PK), were upreg-
ulated by HNF4α overexpression, as reported previously
[14]. Surprisingly, we found a 19.29-fold increase of PPARγ
expression with Ad-rHNF4α infection relative to the Ad-
GFP control (Table 1). Meanwhile, the expression of Srebf1,
a gene encoding a major transcriptional regulator SREBP-1c,
which is important in triglyceride metabolism, showed a
1.53-fold decrease in expression (data not shown). The
upregulation of PPARγ, including PPARγ1a n dP P A R γ2, by
HNF4α overexpression was conﬁrmed by quantitative real-
time PCR (Figure 1(a)). To assess whether HNF-4α contrib-
utes to the transactivation of PPARγ, we performed PPRE-
driven luciferase reporter assays in the human hepatic cell
line HepG2. Rosiglitazone, the PPARγ agonist, was used as a
positive control. Compared with control cells cotransfected
with vehicle plasmid, the PPRE-luc activity was induced by
HNF-4α co-transfection, and BADGE, the PPARγ antag-
onist, could diminish this eﬀect (Figure 1(b)), which sug-
gests that HNF-4α transactivated PPRE-luc activity through
PPARγ.
3.2. HNF4α Is Involved in PPARγ2Transactivation. Sequence
comparison by BLAST analysis revealed more than 80% sim-
ilarity in the PPARγ2p r o m o t e rb u tn o tP P A R γ1p r o m o t e r
between human and rat. We identiﬁed a putative HNF4α site
on the human PPARγ2 promoter (in the region of −842
to −827) by the prediction program of the CREAD plat-
form (PKUHSC) (Figure 2(a)). ChIP assay revealed that4 PPAR Research
Table 2: Body weight, organ weights, and plasma metabolic values in adenovirus-infected rats.
Ad-GFP Ad-HNF4α
Body weight (g) 204.1 ±5.910 214.3 ±5.877
Liver weight (g) 9.187 ±0.5127 10.51 ±0.5530
Liver weight to body weight 0.04493 ±0.001696 0.04901 ±0.002013
Insulin (uIU) 22.21 ±0.7384 20.15 ±1.647
Plasma triglycerides (mg/dl) 36.02 ±4.798 46.94 ±6.107
Liver triglycerides (mg/g·dl) 1.532 ±0.3019 1.088 ±0.0799
Basal glucose (mmol/dl) 5.167 ± 0.1626∗ 6.150 ±0.1565
∗P<0.05 compared with control group.
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Figure 1: Hepatic nuclear factor 4α(HNF4α) induced peroxisome proliferator-activated receptor γ (PPARγ) transcription activity in
hepatocytes. (a) Quantitative RT-PCR (qRT-PCR) analysis of mRNA levels of PPARγ and its subtypes PPARγ1a n dP P A R γ2 in isolated
primary hepatocytes. (b) HepG2 cells were cotransfected with plasmids of 3 × PPRE-Luc reporter plasmid with pMT7-HNF4α or vehicle
plasmid for 24hr, and luciferase activity with PPARγ antagonist BADGE and agonist rosiglitazone (Rosig) was measured. The β-gal plasmid
was cotransfected as a transfection control. Promoter activities were measured by relative luciferase activity, which was normalized to that
of β-gal. Results are mean ± SEM mRNA levels normalized to that of β-actin and expressed as fold of control group (DMSO). Results are
representative of 3 independent experiments. ∗P<0.05, ∗∗P<0.01.
HNF4α could bind to the predicted HNF4α binding site on
the PPARγ2p r o m o t e r( Figure 2(b)). Moreover, quantitative
PCR with PPARγ2 promoter sequence-speciﬁc primers re-
vealed that HNF4α overexpression enhanced the promoter
occupancy of HNF4α on the PPARγ2p r o m o t e r( Figure
2(b)). Transient transfection assay with a series of 5 -dele-
tion reporter constructs containing diﬀerent lengths of the
PPARγ2 promoter revealed that deletion of 893 to 502 bp in
the promoter region led to a large decrease in the ability of
HNF4α to transactivate the PPARγ2p r o m o t e r( Figure 2(c)).
3.3. Hepatic Overexpression of HNF4α in Rat Lowered Plasma
and Liver Cholesterol Levels. To ascertain the role of HNF4α-
upregulated PPARγ in liver in vivo, rats were injected with
Ad-HNF4α or Ad-GFP intravenously and killed 7 days later.
Overexpression of HNF4α in liver signiﬁcantly increased
hepatic HNF4α protein level (Figure 3(a)) as compared with
Ad-GFP-infected controls. mRNA levels of HNF4α target
genes (Pepck, G6p, Apob, Apoc3, and L-pk) in liver were ele-
vated by Ad-HNF4α (Figure 3(b)). The rats showed normal
body weight, liver weight, plasma insulin level (Table 2), and
oral glucose tolerance (data not shown). Plasma level of tri-
glycerides was increased but not signiﬁcantly (Table 2). Oil-
red O staining showed no lipid accumulation in the liver
( d a t an o ts h o w n ) .H o w e v e r ,c h o l e s t e r o ll e v e l sw e r er e d u c e d
in both plasma and liver (Figures 3(c) and 3(d)). Plasma
lipoprotein analysis revealed decreased LDL-C but not HDL-
Cf r a c t i o n( Figure 3(c)).
3.4. Selective Regulation of Hepatic Cholesterol-Regulatory
Genes by HNF4α in Liver. To study the mechanism of
HNF4α-regulated cholesterol metabolism in liver, we exam-
ined the expression of pivotal genes governing liver choles-
terol metabolism in rat liver with HNF4α overexpression.
qPCR results revealed elevated mRNA levels of hepatic
PPARγ and its known target gene CYP7α1[ 15], as expected
(Figure 4(a)). Genes regulating lipoprotein uptake, such as
LDL receptor and scavenger receptor class B type I (SR-BI),
were also upregulated. However, genes regulating cholesterol
de novo synthesis, eﬄux and metabolism, such as ABCA1,
ABCG5, ABCG8, and HMG-CoA reductase showed no reg-
ulation by HNF4α. Intriguingly, the mRNA level of lecithin:PPAR Research 5
tgtgccatcg tgtctggatt actttgtagta t a a gtaaat ttccaagcat ggggaggaaa
ggagaagctc ctttattgag aattcaactg aatatagaga aaactaattt tacacaactg
taatcactgta gtcatttgg acaaattagca a a c c c a a gt tttgctttaa cttggattgc
cttaataaag atgttttggg gcttaatggca c a gttgctc aactccccca ctttattccg
tgatgttcag acccagccag catttcccca tcaggctctt gcaccatgat tgacagggac
acttttacta gtccccttgaa gaatgaata gttactcaat ggagattaac cagatatata
tttattttac tcagaatatc acgataagta taa t tcagag aattattgcc ttctaatata
ctgccctgtg tgggggcgtc tttgaaagtc cgcaaagtca ctgcaattct aataggccac
tcatgtgaca agacctgctc ccacatcggta a t t t ggcac agctagtatt tctccttgcc
aaaaagggca aaggccttga gcaagaagcc agctttttcc tgattacaaa actgaccaca
attcctcgcc aacctaacag cgtaagtcta tttttttctgg tggtgtgtt attcttctca
tagagaactc cattttttca ttatgacata gcacttatcg tttaaacatc aattgatgtt
caaacatcag ctggtgtaac attgctgcag ttgctattgat ggataagct gaagttttta
agaaagcaaa cccgatgtat aaaattgaaa ccatatcaaa cccttcttca ttctctcagc
tatttaattt tacagaattt agatagcagtc a gtatcatt ttgggcttca caaatcagta
gagtaagtac cttaggaata taacatttca gtagcatgct gataccaacg tttaaactat
ggatacatat ttgaattcca aatttttctt caaataatgt gattagagat tcaaccagga
atagacaccg aaagaaaact ttgcccaaat aagctttctgg tatttcata agcaagagat
ttaagttttc catttaagaa gcaattgtga attttacaac aataaaaaat gcaagtggat
attgaacagtc t c t gctctg ataattctaa atacagtaca gttcacgccc ctcacaagac
actgaacatg tgggtcaccgg cgagacagt gtggcaatat tttccctgta atgtaccaag
tcttgccaaa gcagtgaaca ttatgacaca actttttgtc acagctggct cctaatagga
cagtgccagc caattcaagcc c a gtccttt ctgtgtttat tcccatctct cccaaatatt
tggaaactgat gtcttgact catgggtgta ttcacaaatt ctgttacttc aagtcttttt
cttttaacgg attgatcttt tgctagatag agacaaaata tcagtgtgaa ttacagcaaa
cccctattcc atgct
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Figure 2: HNF4α transactivated PPARγ2 promoter in hepatocytes. (a) Sequence of the 1.6-kb cloned human PPARγ2p r o m o t e ra n ds k e t c h
of putative HNF4α binding site. (b) HepG2 cells were infected with or without adenovirus HNF4α (Ad-HNF4α) for 24hr and underwent
chromatin immunopreciptitation (ChIP) assay with anti-HNF4α antibody; normal rabbit IgG was used in control experiments. qPCR was
used with PPARγ promoter-speciﬁc primers to detect binding of HNF4α to the PPARγ2 promoter. The DNA levels were normalized to
that of input and expressed as fold of the control group. ∗P<0.05. (c) HepG2 cells were cotransfected with plasmids of PPARγ2p1505-
Luc, PPARγ2p893-Luc, or PPARγ2p502-Luc with pMT7-HNF4α or vehicle plasmid. The β-gal plasmid was cotransfected as a transfection
control. Promoter activities were measured by relative luciferase activity, with the level normalized to that of β-gal, from 3 independent
experiments, each performed in triplicate. Data are mean ± SD. ∗∗P<0.01 compared with control.6 PPAR Research
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Figure 3: Hepatic overexpression of HNF4α in rats decreased cholesterol levels in both plasma and liver. Rats were intravenously injected
with Ad-HNF4α or Ad-GFP (n = 6), then killed 7 days post-infection. (a) Liver extracts were used to determine protein expression by
western blot analysis with antibodies against HNF4α or β-actin. (b) Relative mRNA levels of hepatic HNF4α target genes, including G6p,
Apoc3, Apob, and L-pk, were examined by qPCR. (c) Plasma cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C) levels were determined. (d) Liver cholesterol was measured in lipid content of rat liver. Data are mean ±
SEM, ∗P<0.05, ∗∗P<0.01 versus Ad-GFP infection.PPAR Research 7
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Figure 4: Expression pattern of hepatic cholesterol-regulatory
genes under HNF4α overexpression in rat liver. (a) Total RNA was
extracted from rat liver and the mRNA levels of hepatic cholesterol-
regulatory genes, including HMGCoAR, LCAT, PLTP, LDLR, SR-BI,
ABCA1, ABCG5, ABCG8, and CYP7A1, were measured by qPCR.
Data are mean ± SEM mRNA levels normalized to that of β-actin
andexpressedasfoldofGFP-infectedgroup. ∗P<0.05.(b)Ratliver
extracts were examined by western blot analysis with antibodies
against SR-BI or β-actin.
cholesterol acyltransferase (LCAT), which converts choles-
terol and phosphatidylcholines (lecithins) to cholesteryl es-
ters and lysophosphatidylcholines on the surface of high-
density lipoproteins [16], was elevated by HNF4α overex-
pression (Figure 4(a)). Therefore, cholesterol uptake genes
seemed to be regulated by HNF4α in liver, possibly via
PPARγ upregulation.
3.5. Upregulation of SR-BI by HNF4α Depended on PPARγ.
SR-BI was found regulated by activators of PPARγ in human
hepatocytes [17] and a PPRE was proved to exist in the hu-
man SR-BI promoter [18]. Western blot analysis conﬁrmed
the upregulation of SR-BI with HNF4α overexpression at
the protein level in vivo in rat liver (Figure 4(b))a n din
vitroinrathepatocytes(Figure 5(b)).Wefurtherinvestigated
the role of HNF4α in SR-BI upregulation in cultured he-
patocytes. The PPARγ antagonist BADGE could attenuate
HNF4α-induced SR-BI expression at both mRNA and pro-
tein levels (Figures 5(a) and 5(b)), which suggests that
HNF4α upregulates SR-BI in a PPARγ-dependent manner.
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Figure 5: HNF4α-upregulated SR-BI depends on PPARγ.R a tp r i -
mary hepatocytes were pretreated with or without PPARγ antago-
nist BADGE (10μM) for 30 min and then infected with Ad-HNF4α
orAd-GFP.(a)Real-timePCRanalysisofmRNAexpressionand(b)
western blot analysis of protein expression from 3 independent ex-
periments.β-actin was used as an internal control. Data are mean ±
S E Mm R N Al e v e l sn o r m a l i z e dt ot h a to fβ-actin and expressed as
fold of control group. ∗P<0.05, ∗∗P<0.01.
4. Discussion
PPARγ is a ligand-activated transcription factor that regu-
lates diverse biological activities and plays major roles in
many diseases, including diabetes mellitus, metabolic syn-
drome, and atherosclerosis [19]. It is highly expressed in adi-
pose tissue, where it plays an essential role in fat storage and
the diﬀerentiation of adipocytes [20]. However, PPARγ is ex-
pressed at low levels in other tissues, including liver. An an-
tidiabetic drug, pioglitazone, a known PPARγ activator, sig-
nificantlyimprovedlipidmetabolismandinsulinresponsive-
ness and reduced the hepatic inﬂammatory response [21].
Among the hepatic expression PPARγ isoforms, though
PPARγ2 has lower expression amount than PPARγ1, it is the
only PPARγ isoform which could be regulated at the tran-
scriptional level by nutrition [22]. Furthermore, PPARγ2i s
the liver isoform that is ectopically induced in response to
excess nutrition or genetic obesity [23]. Here, we show that8 PPAR Research
PPARγ is a direct target gene of HNF4α in rat, and HNF4α
overexpressionmayachieveitscholesterol-loweringeﬀectvia
PPARγ-SR-BI upregulation. Martinez-Jimenez et al. showed
that HNF4α can bind to and activate the PPARγ1p r o m o t e r ,
andthetranscriptionalcofactorHes6interactedwithHNF4α
to prevent the hepatic transactivation of PPARγ1[ 24]. In ad-
dition to Martinez’s work, our data demonstrate a functional
HNF4-responsive element on the PPARγ2 promoter. HNF4α
could upregulate both PPARγ1a n dP P A R γ2 in our gain-
of-function model with overexpression of HNF4α. We did
not investigate the involvement of hepatic Hes6. Recently,
HNF4α was proved to have the ability to bind with RXRα,a
classical PPARγ transcriptional cofactor [25]. The fold acti-
vation of PPARγ by HNF4α overexpression diﬀered in vivo
and in vitro and that might result from the varied combi-
natiorial regulation of various factors including ligands and
other transcription factors. The authors do not exclude the
possibility that overexpression of HNF4α may change the ex-
pression pattern of PPARγ transcription variants.
Expression of PPARγ in the liver was augmented in mu-
rine steatosis, and adenovirus-mediated overexpression of
PPARγ in the liver provokes steatosis [26, 27]. Surprisingly,
we did not observe any signiﬁcant change in hepatic steato-
sis in Ad-HNF4α-treated rats. In a previous study, coexpres-
sion of HNF4α increased the promoter activity of PPARα
[28]. TZD18, a potent agonist with dual PPARα/γ agonist
activities, aﬀected lipid homeostasis, thus leading to an anti-
atherogenic plasma lipid proﬁle [29]. Our results showed
reduced LDL-C level and upregulation of PPARγ by HNF4α.
HNF4α might be a dual PPARα/γ activator, and overexpres-
sion of HNF4α may be eﬀective in treatment of type 2 di-
abetes and dyslipidemia and in preventing atherosclerotic
cardiovascular disease.
Cholesterol homeostasis depends on proper control of
cholesteroluptake,denovosynthesis,eﬄux,andmetabolism.
HNF4α is highly expressed in the liver and regulates numer-
ous genes involved in energy metabolism. Decreased choles-
terol, HDL cholesterol, and triglyceride levels found in the
plasma of mice lacking hepatic HNF4α [10] suggests that
HNF4α plays an important role in controlling hepatic lipid
metabolism and transport. In our previous study, we found
that HNF4α was sensitive to plasma insulin level and was
downregulated by SREBPs in hyperinsulinemia diabetes [11]
and hepatic SREBPs were downregulated by HNF4α overex-
pression in mice (unpublished data). Compared with knowl-
edge from loss-of-function study [10], the one of the role
HNF4α in gain-of-function animal models is limited. In the
loss-of-function model of liver-speciﬁc HNF4α deﬁciency,
authors attributed the decrease of the serum cholesterol to
the reduced de novo cholesterol biosynthesis, VLDL secre-
tion, and HDL biogenesis [10, 30]. However, our data re-
vealed that hepatic HNF4α overexpression mainly aﬀect the
uptake of circulating cholesterol in rat liver. Overexpression
of HNF4α in the liver lowered the plasma level of LDL-C
but had little eﬀect on HDL-C and triglyceride levels in plas-
ma and liver. These data indicate that HNF4α overexpression
might have a moderate cholesterol-lowering eﬀect. Further
dissection of genes pivotal in the control of hepatic choles-
terol homeostasis in the rat liver revealed that HNF4α
overexpression mainly enhanced the expression of genes in-
volvedincholesteroluptake.Thisresultisinaccordancewith
those of a recent study of a similar gain-of-function mouse
model [30].
The role of SR-BI in the hepatic hypocholesterolemic
eﬀect under hepatic HNF4α deﬁciency is still controversial:
Hayhurst et al. attributed the cholesterol-lowering eﬀect to
increased hepatic SR-BI expression [10] while in an acute
liver-speciﬁc loss of function model, Yin et al. demonstrated
an elevation in liver SR-BI level [30]. In compensated for the
mice data, we have provided in vivo and in vitro gain-of-
function data on rats.
We found the mRNA level of LDLR and SR-BI but not
ABCG5 were upregulated. Moreover, the fold upregulation
of SR-BI is higher than LDLR in our in vivo data. It has
been reported previously that HNF4α could interact with
SREBP-2 on the sterol-response-element (SRE) of the LDLR
promoter and hence modulate its transcriptional activity
[28]. The hepatic upregulation of SR-BI was found to de-
crease LDL-C and HDL-C content in mice [31]. We further
found overexpression of HNF4α upregulated the protein
level of SR-BI in vivo. Our ﬁnding together with the data
from the HNF4α-knockout mice research suggests that the
regulation of SR-BI by HNF4α might be indirect. In this
study, we showed that overexpression of HNF4α in isolated
rat primary hepatocytes induced SR-BI, whereas inhibition
of PPARγ diminished this eﬀect, which suggests the involve-
ment of HNF4α-induced PPARγ transactivation. In addi-
tion, rosiglitazone, a known PPARγ-agonist, signiﬁcantly
augmentedthestimulationeﬀectofHNF4αonSR-BImRNA
level. The synergistic eﬀect of PPARγ-ligand and HNF4α
overexpression gave us further evidence to support the idea
that the elevation of SR-BI induced by enhanced HNF4α
expressionlevelisduetotheHNF4α-inducedtransactivation
of PPARγ. These ﬁndings indicate that HNF4α induced
upregulation with the involvement of PPARγ transactivation
in liver might, at least in part, account for the cholesterol-
lowering eﬀect of hepatic HNF4α overexpression.
We noticed that there was a signiﬁcant diﬀerence of basal
g l u c o s el e v e l sw i t hh e p a t i cH N F 4 α overexpression than the
control rats. This might attribute to the elevation of impor-
tant glucose metabolic genes, including Pepck, G6pc,a n dL-
pk. They are known HNF4α-target genes and can be upreg-
ulated to maintain an appropriate circulating glucose level
while fasting. However, we did not observe any interruption
caused by hepatic HNF4α overexpression in the oral glucose
tolerance test on rats. The role of hepatic HNF4α in glucose
metabolism is worth future investigation.
Rat livers exposed to Ad-PPARγ showed signiﬁcantly less
ﬁbrosisthandidcontrols[32],andoverexpressionofHNF4α
alleviated hepatic ﬁbrosis in rats with bile duct ligation [33].
HNF4α may prevent hepatic stellate cell activation and thus
ameliorate liver steatosis through transactivation of PPARγ.
Because of evidence of the interaction between PPARγ2a n d
HNF4α contributing to variation in insulin sensitivity in
Mexican Americans [34], more work is needed to uncover
the role of HNF4α and PPARγ in various human diseases.
In summary, we demonstrate that HNF4α transcription-
ally upregulates PPARγ2 by directly binding to the PPARγ2PPAR Research 9
promoter. We also reveal the regulatory role of HNF4α in
liver lipid metabolism by modulating the expression of cho-
lesterol metabolism-associated genes. These eﬀects were, at
leastinpart,duetotheupregulationofSR-BIthroughtheac-
tivation of PPARγ by HNF4α.
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